Ampio Pharmaceuticals details early positive results for inhaled Ampion in COVID-19 distress
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in... Read More
Wednesday March 17, 2021 0 comments
Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following... Read More
Friday December 4, 2020 0 comments
Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the second group in the Phase I inhaled Ampionclinical study is being treated following clearance by the Safety Monitoring... Read More
Wednesday November 11, 2020 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
